CCO Treatment Updates
Clinical Issues and Future Directions in Hematologic Malignancies
Virtual Presentations
Clinical Issues and Future Directions in Hematologic Malignancies: Multiple Myeloma
|
|
|
 Listen to William I. Bensinger, MD, present the most up-to-date data from the 2006 Hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with multiple myeloma. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the results of recent studies on the use of FDA-approved and investigational agents for the treatment of multiple myeloma
- Review new data regarding the use of stem cell transplantation in patients with multiple myeloma
|
CCO Slideset – Clinical Issues and Future Directions in Hematologic Malignancies: Multiple Myeloma
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 589 KB
|
Clinical Issues and Future Directions in Hematologic Malignancies: Non-Hodgkin’s Lymphoma
- Owen A. O'Connor, MD, PhD
|
|
|
Listen to Owen A. O’Connor, MD, PhD, present the most up-to-date data from the 2006 Hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with non-Hodgkin’s lymphoma. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the results of recent studies on the use of FDA-approved and investigational agents for the treatment of non-Hodgkin’s lymphoma
- Discuss new insights into the etiology and pathogenesis of non-Hodgkin’s lymphoma
- Summarize the use of prognostic markers in the management of non-Hodgkin’s lymphoma
|
CCO Slideset – Clinical Issues and Future Directions in Hematologic Malignancies: Non-Hodgkin’s Lymphoma
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 735 KB
|
Clinical Issues and Future Directions in Hematologic Malignancies: Myelodysplastic Syndromes and Acute Leukemias
|
|
|
Listen to Farhad Ravandi, MD, present the most up-to-date data from the 2006 Hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with myelodysplastic syndromes and acute leukemias. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the results of recent studies of the use of FDA-approved and investigational agents for the treatment of myelodysplastic syndromes and acute leukemias
- Discuss new insights into the etiology and prognostic indicators of myelodysplastic syndromes and acute leukemias
- Identify new developments in the classification of patients with myelodysplastic syndromes and acute leukemias
|
CCO Slideset – Clinical Issues and Future Directions in Hematologic Malignancies: Myelodysplastic Syndrome and Acute Leukemias
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 655 KB
|
Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Myeloid Leukemia
|
|
|
Listen to Moshe Talpaz, MD, present the most up-to-date data from the 2006 Hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with chronic myeloid leukemia. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the results of recent studies on the use of FDA-approved and investigational agents for the treatment of chronic myeloid leukemia
- Discuss new insights into the etiology and prognostic indicators of chronic myeloid leukemia
- Review new data regarding the use of stem cell transplantation in patients with chronic myeloid leukemia
|
CCO Slideset – Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Myeloid Leukemia
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 428 KB
|
Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Lymphocytic Leukemia
- Michael J. Keating, MB BS
|
|
|
Listen to Michael J. Keating, MB BS, present the most up-to-date data from the 2006 Hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with chronic lymphocytic leukemia. Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the results of recent studies on the use of FDA-approved and investigational agents for the treatment of chronic lymphocytic leukemia
- Discuss new insights into the etiology and prognosis of chronic lymphocytic leukemia
- Summarize current strategies for combining targeted therapies with conventional chemotherapy for the treatment of chronic lymphocytic leukemia
|
CCO Slideset – Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Lymphocytic Leukemia
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 455 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|